Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/Naloxone vs Codeine/Paracetamol in OA Pain
NCT02032927Phase 4Withdrawn
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of oxycodone + naloxone in osteoarthritis (OA) (2 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Efficacy and tolerability at 15 days. Planned start Jun 2013; status: withdrawn.
02
Drugs
oxycodone + naloxone
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02032927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032927.